Gdańsk, Poland | 22–24 April 2027
19:00
Get-together (Faculty Only)
Gdańsk, Poland | 22–24 April 2027
08:30 – 08:35
Welcome prof. dr hab. n. med. Krzysztof Narkiewicz, prof. Michel Burnier
5 min
08:35 – 09:50
Session 1. From biomarkers to clinical decisions — what really changes practice Chairs: prof. dr hab. n. med. Andrzej Januszewicz, prof. Alexandre Persu
75 min

08:35 - 08:50

Why do we need biomarkers — what do they add beyond conventional risk factors? Carmine Zoccali

08:50 - 09:05

Different biomarkers, different questions Francesca Mallamaci

09:05 - 09:20

From association to clinical utility — how should a new biomarker be validated? prof. Christian Delles

09:20 - 09:35

When should a biomarker change treatment?

09:35 - 09:50

Discussion
09:50 – 10:10
Coffee break 20 min
10:10 – 12:10
Session 2. Hypertension in 2027: promises and disappointments in biomarkers, risk stratification and treatment targets
120 min

10:10 - 10:25

Homocysteine and B vitamins — old story, new evidence?

10:25 - 10:40

Inflammation and vascular dysfunction in hypertension — does hsCRP add value? Daniela Carnevale

10:40 - 10:55

hs-Troponin and NT-proBNP — ready for risk stratification in hypertension? prof. Gianfranco Parati

10:55 - 11:10

MicroRNAs — still promising or a missed opportunity?

11:10 - 11:25

Renin and aldosterone — can we use them to guide treatment?

11:25 - 11:40

Sympathetic activation — can we identify and treat the phenotype? Stefano Masi

11:40 - 12:10

Discussion
12:30 – 14:00
Lunch
90 min
14:00 – 16:00
Session 3. Biomarkers in CKD — from progression to nephroprotective treatment Chairs: Liffert Vogt, prof. Michel Burnier
120 min

14:00 - 14:15

New blood and urine biomarkers — do they improve risk prediction?

14:15 - 14:30

Tubular biomarkers — can they improve assessment of kidney injury and progression? . Marius Miglinas

14:30 - 14:45

Albuminuria and eGFR slope — still the benchmarks? Alberto Ortiz

14:45 - 15:00

Afamin — promising biomarker or another association?

15:00 - 15:15

pre-CKD (hrCKD) — new clinical entity in nephrology defined by biomarkers prof. dr hab. n. med. Marcin Adamczak

15:15 - 15:30

From risk prediction to treatment selection — can biomarkers guide nephroprotection? prof. dr hab. n. med. Andrzej Więcek

15:30 - 16:00

Discussion
16:00 – 16:20
Coffee break 20 min
16:25 – 17:35
Session 4. Heart Failure: from biomarkers to precision therapy and proactive care Chairs: prof. Gianfranco Parati, Piotr Ponikowski
70 min

16:25 - 16:32

From molecular signatures to treatable endotypes: can multi-omics guide heart failure therapy?

16:32 - 16:44

Precision decongestion: urine sodium and beyond dr hab. n. med., prof. UMW Jan Biegus

16:44 - 16:56

From blood tests to biosensors: towards real-time monitoring in heart failure

16:56 - 17:08

From multi-modal monitoring to supported self-management: can we prevent worsening heart failure?

17:08 - 17:20

Biomarker-guided precision medicine in heart failure: promise or clinical reality? prof. dr hab. n. med. Ewa Jankowska

17:20 - 17:35

Panel discussion: from biomarker signals to clinical decisions — what is ready for practice?
Gdańsk, Poland | 22–24 April 2027
09:00 – 10:15
Session 5. Beyond blood biomarkers — digital phenotyping and imaging
75 min

09:00 - 09:15

Digital biomarkers in peripheral artery disease — ready for clinical use?

09:15 - 09:30

Renal MRI biomarkers — from tissue characterization to clinical decisions

09:30 - 09:45

Imaging biomarkers for Kidney Function and Disease: MRI and beyond dr Anna Caroli

09:45 - 10:00

Cardiac CT and MRI biomarkers — what changes clinical management?

10:00 - 10:15

Discussion
10:15 – 10:35
Coffee break 20 min
10:35 – 11:50
Session 6. The future of biomarkers — what comes next? Chairs: dr Jan Danser, prof. dr hab. n. med. Krzysztof Narkiewicz
75 min

10:35 - 10:50

From biomarkers to physiology — what can we learn from the kidney?

10:50 - 11:05

Will genetic biomarkers change clinical practice? Olle Melander

11:05 - 11:20

Risk assessment in hypertension — where will biomarkers fit?

11:20 - 11:35

From cardiovascular risk prediction to treatment — which biomarkers will really matter in 2030?

11:35 - 11:50

Discussion
11:50 – 12:30
 Discussion and closure of the meeting Chairs: prof. dr hab. n. med. Krzysztof Narkiewicz, prof. Michel Burnier
40 min
13:00
Lunch
Copyrights © 2026 Via Medica